ArticleAmerican journal of translational research2025
Plasma SFRP2 hypermethylation as a diagnostic biomarker for dilated cardiomyopathy detected by methylation-specific PCR.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exercise-specific epigenetic effects on cardiovascular health.Clinical epigenetics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the clinical utility of plasma Secreted Frizzled-Related Protein 2 (SFRP2) gene hypermethylation as a non-invasive epigenetic biomarker for diagnosing Dilated cardiomyopathy (DCM) and stratifying cardiac function.
methodsA retrospective cohort of 482 participants (241 DCM patients and 241 healthy controls) was analyzed. DCM patients were further stratified by New York Heart Association (NYHA) class into better cardiac function (BCF; NYHA I-II) and poor cardiac function (PCF; NYHA III-IV) groups. Methylation-specific polymerase chain reaction (MSP) was used to assess SFRP2 methylation levels. Statistical analyses evaluated its diagnostic value, including receiver operating characteristic (ROC) curve analysis to determine sensitivity and specificity.
resultsPlasma SFRP2 methylation levels were significantly higher in DCM patients than in controls (P < 0.001). ROC analysis revealed an area under the curve (AUC) of 0.942, indicating excellent diagnostic performance. Among DCM patients, the PCF group exhibited significantly higher SFRP2 methylation levels compared to the BCF group (P < 0.001). Additionally, SFRP2 methylation showed a strong positive correlation with worsening cardiac function (r = 0.786, P < 0.001).
conclusionElevated plasma SFRP2 methylation levels in DCM patients, particularly those with poor cardiac function, demonstrate its high diagnostic accuracy and potential to reflect disease severity, supporting its use as a non-invasive clinical biomarker for DCM diagnosis and risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.